Literature DB >> 17847635

Third-party risks in research: should IRBs address them?

Daniel M Hausman1.   

Abstract

Mesh：

Year:  2007        PMID： 17847635

Source DB:  PubMed          Journal:  IRB        ISSN： 0193-7758


× No keyword cloud information.
  9 in total

Review 1.  Regulating impact on bystanders in clinical trials: An unsettled frontier.

Authors:  Nir Eyal; Jonathan Kimmelman; Lisa G Holtzman; Marc Lipsitch
Journal:  Clin Trials       Date:  2019-08-01       Impact factor: 2.486

2.  Opinion: Risk to study nonparticipants: A procedural approach.

Authors:  Nir Eyal; Marc Lipsitch; Till Bärnighausen; Dan Wikler
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-07       Impact factor: 11.205

3.  Using, risking, and consent: Why risking harm to bystanders is morally different from risking harm to research subjects.

Authors:  Alec Walen
Journal:  Bioethics       Date:  2020-04-07       Impact factor: 1.898

4.  Bystanders, risks, and consent.

Authors:  Helen Frowe
Journal:  Bioethics       Date:  2019-10-25       Impact factor: 1.898

5.  Patient perspectives on group benefits and harms in genetic research.

Authors:  A J Goldenberg; S C Hull; B S Wilfond; R R Sharp
Journal:  Public Health Genomics       Date:  2010-10-08       Impact factor: 2.000

6.  Environmental Health Research Involving Human Subjects: Ethical Issues.

Authors:  David B Resnik
Journal:  Environ Health Insights       Date:  2008-07-14

7.  Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field.

Authors:  Leili Fatehi; Susan M Wolf; Jeffrey McCullough; Ralph Hall; Frances Lawrenz; Jeffrey P Kahn; Cortney Jones; Stephen A Campbell; Rebecca S Dresser; Arthur G Erdman; Christy L Haynes; Robert A Hoerr; Linda F Hogle; Moira A Keane; George Khushf; Nancy M P King; Efrosini Kokkoli; Gary Marchant; Andrew D Maynard; Martin Philbert; Gurumurthy Ramachandran; Ronald A Siegel; Samuel Wickline
Journal:  J Law Med Ethics       Date:  2012       Impact factor: 1.718

8.  How to Address the Risk of HIV Transmission in Remission Studies With Treatment Interruption: The Low-Hanging Fruit Approach.

Authors:  Nir Eyal
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

9.  Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection.

Authors:  Adam Gilbertson; Joseph D Tucker; Karine Dubé; Maartje Dijkstra; Stuart Rennie
Journal:  BMC Med Ethics       Date:  2021-12-28       Impact factor: 2.652
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.